Kidney rejection initiated by antibodies that were present before transplantation is linked with a better outcome that rejection due to antibodies that arise after transplantation
New research provides insights on transplant recipients’ antibody responses against donor kidneys and how the timing of those responses can have important implications. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
An antibody response against donor organs is the main cause of kidney rejection following transplantation. Antibodies can occur in 2 scenarios: before transplantation (preexisting donor-specific antibodies) and after transplantation (de novo donor-specific antibodies). Little is known about how these processes compare.
Understanding the role of antibodies in transplant rejection is needed to guide matching of donors and recipients and to better prevent rejection. A team led by Alexandre Loupy, MD, PhD, Olivier Aubert, MD (INSERM U 970, Paris Translational Research Center for Organ Transplantation, in France), and Phil Halloran, MD, PhD (Alberta Transplant Applied Genomics Centre, in Canada) studied 205 patients who experienced antibodymediated rejection following kidney transplantation: 103 patients had pre-existing donorspecific antibodies and 102 patients had de novo donor-specific antibodies. There were various differences between patients with pre-existing vs. de novo donorspecific antibodies, but the most striking was the superior kidney survival experienced by the pre-existing group compared with the de novo group (63% vs. 34% at 8 years after rejection, respectively), regardless of treatment.
The American Society of Nephrology®, ASN®, Kidney Week®, CJASN®, JASN®, NephSAP®, and ASN Kidney News® are registered trademarks of ASN “Our results encourage the transplantation of patients who have antibodies before transplant.
These patients would not normally have been considered as good candidates for transplantation and would have stayed on dialysis because of a high level of sensitization that prevents from finding a compatible kidney,” said Dr. Loupy. The findings also indicate the need to closely monitor patients for the development of de novo donorspecific antibodies so that therapies can be initiated to preserve kidney function.
The article, entitled “Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients,” was published on March 2, 2017, doi: 10.1681/ASN.2016070797.
Paris Transplant Group
Our global aim is to accelerate the translation of immunological and gene expression discoveries into the clinical field by filling the gap between basic science and applied biomedical researches.